35
views
0
recommends
+1 Recommend
0 collections
    3
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Geographic Variation in Pediatric Cancer Incidence — United States, 2003–2014

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Approximately 15,000 persons aged <20 years receive a cancer diagnosis each year in the United States ( 1 ). National surveillance data could provide understanding of geographic variation in occurrence of new cases to guide public health planning and investigation ( 2 , 3 ). Past research on pediatric cancer incidence described differences by U.S. Census region but did not provide state-level estimates ( 4 ). To adequately describe geographic variation in cancer incidence among persons aged <20 years in the United States, CDC analyzed data from United States Cancer Statistics (USCS) during 2003–2014 and identified 171,432 cases of pediatric cancer during this period (incidence = 173.7 cases per 1 million persons). The cancer types with the highest incidence rates were leukemias (45.7), brain tumors (30.9), and lymphomas (26.2). By U.S. Census region, pediatric cancer incidence was highest in the Northeast (188.0) and lowest in the South (168.0), whereas by state (including the District of Columbia [DC]), rates were highest in New Hampshire, DC, and New Jersey. Among non-Hispanic whites (whites) and non-Hispanic blacks (blacks), pediatric cancer incidence was highest in the Northeast, and the highest rates among Hispanics were in the South. The highest rates of leukemia were in the West, and the highest rates of lymphoma and brain tumors were in the Northeast. State-based differences in pediatric cancer incidence could guide interventions related to accessing care (e.g., in states with large distances to pediatric oncology centers), clinical trial enrollment, and state or regional studies designed to further explore variations in cancer incidence. USCS includes incidence data from CDC’s National Program of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program ( 1 ). Data on new cases of cancer diagnosed during 2003–2014 were obtained from population-based cancer registries affiliated with NPCR and SEER programs in all U.S. states and DC. This study included incidence data for all registries that met USCS publication criteria* during 2003–2014, which represented >99% of the U.S. population, excluding data only from Nevada, which did not meet criteria in 2011. This report includes all cases of malignant † cancer diagnosed among persons aged <20 years; it includes first primary cases only and excludes recurrent cases. Diagnosis histology and primary site were grouped according to the International Classification of Childhood Cancer (ICCC). § Pediatric cancer rates were expressed per 1 million persons and were age-adjusted to the 2000 U.S. standard population. ¶ Rates were estimated by sex, age group, race/ethnicity, state, U.S. Census region,** county-level economic status, county-level rural/urban classification, and ICCC group. During 2003–2014, CDC identified 171,432 new cases of pediatric cancer (Table 1). Overall incidence was 173.7 cases per 1 million population. The cancer types with the highest incidence rates were leukemias (45.7 per 1 million), brain tumors (30.9), and lymphomas (26.2). Rates were higher in males (181.5) than in females (165.5) and in persons aged 0–4 years (228.9) and 15–19 years (213.3) than in persons aged 5–9 years (122.6) and 10–14 years (133.0). Among all racial/ethnic groups, the highest incidence rate was among whites (184.4), and the lowest was among blacks (133.3). TABLE 1 Age-adjusted incidence rate* of cancer † among persons aged <20 years, by U.S. Census region § — United States, ¶ 2003–2014 U.S. Census region Total Northeast Midwest South West Characteristic No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) Overall 171,432 173.7 (172.9–174.5) 31,893 188.0 (185.9–190.0) 37,702 172.9 (171.1–174.6) 61,998 168.0 (166.7–169.3) 39,839 172.9 (171.2–174.6) Sex Male 91,667 181.5 (180.3–182.7) 16,860 194.5 (191.6–197.5) 20,228 180.3 (178.8–182.8) 33,045 175.1 (173.3–177.0) 21,534 182.3 (179.9–184.8) Female 79,765 165.5 (164.3–166.6) 15,033 181.1 (178.2–184.0) 17,474 164.3 (161.6–166.5) 28,953 160.6 (158.7–162.4) 18,305 163.0 (160.7–165.4) Age group (yrs) 0–4 54,419 228.9 (227.0–230.8) 9,467 242.7 (237.9–247.7) 12,001 227.0 (228.3–230.6) 20,161 222.7 (219.7–225.8) 12,790 226.1 (222.2–230.0) 5–9 29,181 122.6 (121.2–124.1) 5,161 128.7 (125.2–132.3) 6,323 121.2 (116.7–124.6) 10,862 121.4 (119.1–123.7) 6,835 123.2 (120.3–126.1) 10–14 33,042 133.0 (131.5–134.4) 6,256 145.1 (141.5–148.7) 7,128 131.5 (126.0–134.0) 12,042 130.4 (128.1–132.7) 7,616 131.9 (128.9–134.8) 15–19 54,790 213.3 (211.5–215.1) 11,009 238.5 (234.0–243.0) 12,250 211.5 (210.0–215.5) 18,933 200.5 (197.7–203.4) 12,598 213.5 (209.8–217.3) Race/Ethnicity** White 103,650 184.4 (183.3–185.5) 21,580 200.8 (198.1–203.5) 28,309 183.3 (177.7–185.9) 34,798 178.9 (177.0–180.8) 18,963 184.9 (182.3–187.5) Black 20,188 133.3 (131.5–135.2) 3,402 143.6 (138.8–148.5) 3,894 131.5 (125.4–135.6) 11,194 131.9 (129.5–134.4) 1,698 132.7 (126.4–139.1) Hispanic 36,197 168.9 (167.2–170.7) 4,758 170.0 (165.2–175.0) 3,473 167.2 (153.5–170.2) 13,250 175.5 (172.5–178.5) 14,716 165.6 (162.9–168.3) AI/AN 1,507 147.6 (140.2–155.2) 53 93.1 (69.7–121.9) 262 140.2 (118.9–155.2) 450 143.7 (130.7–157.6) 742 162.3 (150.8–174.5) API 7,089 144.6 (141.2–148.0) 1,488 151.8 (144.2–159.8) 937 141.2 (133.6–148.0) 1,402 127.7 (121.1–134.6) 3,262 150.4 (145.3–155.7) County-level economic status by percentile†† ≤25% 19,536 165.7 (163.4–168.0) 1,848 173.7 (165.9–181.9) 2,888 163.4 (162.3–168.7) 9,902 164.6 (161.3–167.8) 4,898 163.9 (159.3–168.5) 25–75% 98,385 171.3 (170.2–172.4) 15,032 182.2 (179.3–185.1) 21,073 170.2 (167.2–172.8) 38,515 167.8 (166.2–169.5) 23,765 172.1 (169.9–174.3) ≥75% 48,268 181.8 (180.2–183.4) 14,996 196.1 (193.0–199.3) 8,894 180.2 (175.8–183.3) 13,252 171.7 (168.8–174.7) 11,126 178.5 (175.2–181.9) County-level rural/urban continuum†† Metropolitan population ≥1 million 93,181 177.1 (176.0–178.3) 21,451 189.2 (186.6–191.7) 15,634 176.0 (171.5–178.0) 31,810 172.0 (170.2–173.9) 24,286 175.9 (173.6–178.1) Metropolitan population 250,000 to <1 million 35,919 171.1 (169.4–172.9) 6,283 184.7 (180.2–189.4) 6,290 169.4 (169.1–172.7) 14,186 164.3 (161.6–167.0) 9,160 172.0 (168.5–175.6) Metropolitan population <250,000 14,349 165.7 (163.0–168.4) 1,556 183.3 (174.2–192.7) 3,958 163.0 (161.0–168.4) 5,721 162.2 (158.0–166.5) 3,114 164.0 (158.3–169.8) Nonmetropolitan counties 22,962 167.2 (165.0–169.3) 2,586 188.8 (181.5–196.3) 6,982 165.0 (165.3–169.3) 10,173 163.0 (159.9–166.2) 3,221 160.8 (155.3–166.4) Sources: CDC’s National Program of Cancer Registries; National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Abbreviations: AI/AN = American Indian/Alaska Native; API = Asian/Pacific Islander; CI = confidence interval. * Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population. † Cases included all malignant cancers (with behavior code = 3) as grouped by the International Classification of Childhood Cancer. § Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. ¶ Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded. Registry-specific data quality information is available at https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2014-technical-notes.pdf. Characteristic values with other, missing, or blank results are not included in this table. ** White, black, AI/AN, and API persons are non-Hispanic. Hispanic persons might be of any race. Counts exclude unspecified or unknown race/ethnicity. †† Excludes Kansas, Minnesota, and Nevada. Rates were highest in the Northeast U.S. Census region, followed by the Midwest, the West, and the South. Rates were highest in the Northeast across all age groups and among whites and blacks. Among Hispanics, rates were highest in the South. Pediatric cancer incidence rates were highest in the 25% of counties with the highest economic status and were higher in metropolitan areas with populations ≥1 million than in nonmetropolitan areas. By state, pediatric cancer incidence rates ranged from 145.2–205.5 per 1 million. Rates were highest in New Hampshire (205.5), DC (194.0), and New Jersey (192.3) and lowest in South Carolina (149.3) and Mississippi (145.2) (Table 2). Incidence among whites ranged from 157.0 in Montana to 255.2 in Hawaii; among blacks, from 105.8 in Rhode Island to 161.3 in Nebraska; and among Hispanics, from 75.0 in Hawaii to 191.8 in Florida. †† Although incidence rates were highest among children aged 0–4 years overall, in some states (e.g., New Jersey, New York, and Illinois), the highest rates were among persons aged 15–19 years (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/53585). TABLE 2 Age-adjusted incidence rate* of cancer † among persons aged <20 years, by state, overall and by race/ethnicity — United States, § 2003–2014 Total Race/Ethnicity¶ White Black Hispanic AI/AN API State** No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) Northeast Connecticut 2,060 185.8 (177.8–194.0) 1,399 194.8 (184.7–205.4) 199 144.6 (125.2–166.3) 361 176.8 (159.0–196.1) —†† —†† 63 133.1 (102.2–170.5) Maine 725 190.5 (176.9–205.0) 685 194.8 (180.4–210.0) —†† —†† —†† —†† —†† —†† —†† —†† Massachusetts 3,584 181.5 (175.6–187.5) —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ New Hampshire 816 205.5 (191.6–220.2) 746 207.6 (192.9–223.2) —†† —†† 31 177.8 (120.6–252.5) —†† —†† 18 157.1 (92.6–249.7) New Jersey 5,308 192.3 (187.1–197.5) 3,168 211.8 (204.4–219.3) 633 148.6 (137.2–160.6) 1,043 175.2 (164.7–186.2) —§§ —§§ 345 145.7 (130.7–162.0) New York 11,378 190.0 (186.5–193.5) 6,679 209.3 (204.3–214.4) 1,538 147.9 (140.6–155.5) 2,290 175.9 (168.7–183.2) —§§ —§§ 701 164.5 (152.5–177.1) Pennsylvania 7,167 186.6 (182.3–191.0) —§§ —§§ —§§ —§§ 494 150.6 (137.6–164.6) —§§ —§§ —§§ —§§ Rhode Island 547 170.0 (156.0–185.0) 429 196.3 (177.9–216.0) 28 105.8 (70.2–153.0) 59 96.8 (73.7–124.9) —†† —†† —†† —†† Vermont 308 164.2 (146.2–183.9) 299 171.1 (152.0–191.9) —†† —†† —†† —†† —†† —†† —†† —†† Midwest Illinois 7,227 171.8 (167.9–175.8) 4,320 183.9 (178.4–189.4) 934 124.4 (116.5–132.7) 1,548 171.2 (162.8–180.0) —§§ —§§ 273 146.7 (129.7–165.2) Indiana 3,691 171.5 (166.0–177.2) 2,957 178.4 (172.0–185.0) 336 127.6 (114.4–142.1) 296 160.7 (142.7–180.4) —†† —†† 55 139.2 (104.7–181.3) Iowa 1,762 178.6 (170.4–187.2) 1,508 181.2 (172.1–190.6) 60 115.7 (88.2–149.1) 130 166.2 (138.6–197.8) —†† —†† 30 140.0 (94.3–200.1) Kansas 1,713 177.0 (168.8–185.6) —§§ —§§ —§§ —§§ 254 172.8 (152.0–195.7) —§§ —§§ —§§ —§§ Michigan 5,786 178.9 (174.3–183.6) 4,339 188.1 (182.6–193.8) 826 140.5 (131.1–150.4) 296 135.8 (120.7–152.3) 34 127.1 (87.8–178.1) 116 122.3 (101.1–146.8) Minnesota 3,109 179.9 (173.6–186.3) 2,420 181.4 (174.3–188.8) 177 122.8 (105.2–142.4) 203 162.6 (140.6–187.0) 46 159.1 (116.4–212.2) 159 162.2 (137.9–189.5) Missouri 3,120 163.1 (157.4–168.9) 2,481 168.9 (162.3–175.6) 400 135.8 (122.8–149.8) 139 137.2 (115.0–162.3) —†† —†† 44 116.5 (84.6–156.5) Nebraska 1,133 183.2 (172.7–194.2) 868 184.9 (172.8–197.7) 69 161.3 (125.3–204.2) 142 165.8 (139.2–196.0) —†† —†† 20 151.2 (92.2–233.7) North Dakota 341 158.7 (142.3–176.6) 295 163.4 (145.2–183.2) —†† —†† —†† —†† 33 174.0 (119.6–244.7) —†† —†† Ohio 6,225 168.3 (164.1–172.5) 4,999 175.6 (170.8–180.6) 751 124.5 (115.8–133.7) 206 122.2 (105.9–140.3) —†† —†† 106 147.5 (120.7–178.6) South Dakota 413 150.3 (136.1–165.5) 347 162.4 (145.8–180.5) —†† —†† —†† —†† 49 126.9 (93.8–167.8) —†† —†† Wisconsin 3,182 175.6 (169.5–181.8) 2,525 181.9 (174.8–189.1) 220 125.1 (109.1–142.7) 247 154.7 (135.7–175.4) 41 181.8 (130.3–246.7) 92 150.1 (120.9–184.1) South Alabama 2,377 157.0 (150.7–163.4) 1,600 172.2 (163.8–180.8) 619 129.4 (119.4–140.1) 102 124.4 (100.7–152.0) —†† —†† 25 133.2 (86.1–196.8) Arkansas 1,523 161.7 (153.7–170.1) —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ Delaware 504 180.9 (165.5–197.5) —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ District of Columbia 306 194.0 (172.6–217.3) 77 215.2 (165.9–274.7) 152 152.0 (128.7–178.2) 28 159.2 (104.6–231.4) —†† —†† —†† —†† Florida 9,160 169.9 (166.4–173.4) 4,625 174.8 (169.8–179.9) 1,526 130.9 (124.4–137.6) 2,714 191.8 (184.7–199.2) —†† —†† 165 111.9 (95.5–130.4) Georgia 5,291 161.9 (157.6–166.3) 2,884 177.1 (170.7–183.6) 1,556 136.2 (129.5–143.2) 634 166.9 (153.8–180.7) —†† —†† 159 144.2 (122.6–168.4) Kentucky 2,377 174.4 (167.4–181.5) —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ —§§ Louisiana 2,378 156.9 (150.7–163.4) 1,453 177.7 (168.7–187.1) 753 127.1 (118.2–136.5) 113 164.2 (134.8–198.0) —†† —†† 42 173.9 (125.3–235.1) Maryland 2,942 160.0 (154.2–165.9) 1,664 179.7 (171.2–188.6) 773 125.1 (116.4–134.3) 286 156.0 (138.1–175.4) —†† —†† 99 95.1 (77.2–115.8) Mississippi 1,476 145.2 (137.9–152.8) 860 166.0 (155.1–177.5) 548 121.7 (111.7–132.4) 45 138.5 (100.2–186.3) —†† —†† —†† —†† North Carolina 4,834 161.6 (157.1–166.2) 3,052 175.2 (169.0–181.5) 991 129.3 (121.4–137.7) 560 155.6 (142.6–169.4) 38 88.7 (62.8–121.8) 111 138.6 (113.9–167.1) Oklahoma 2,082 168.3 (161.1–175.6) 1,273 166.1 (157.0–175.4) 170 131.0 (112.0–152.2) 276 168.9 (149.2–190.4) 296 194.1 (172.6–217.5) 36 142.5 (99.8–197.4) South Carolina 2,162 149.3 (143.1–155.8) 1,370 164.7 (156.1–173.6) 600 122.2 (112.6–132.4) 149 154.4 (130.0–182.0) —†† —†† 24 114.2 (73.1–170.0) Tennessee 3,411 172.1 (166.4–178.0) 2,500 180.4 (173.4–187.6) 614 144.5 (133.3–156.4) 211 160.4 (138.7–184.4) —†† —†† 48 142.2 (104.7–188.6) Texas 16,368 183.2 (180.4–186.0) 6,598 200.7 (195.8–205.6) 1,571 140.0 (133.1–147.1) 7,503 179.7 (175.6–183.8) 47 162.0 (118.8–216.0) 431 134.0 (121.6–147.3) Virginia 3,899 156.4 (151.5–161.4) 2,553 169.2 (162.7–175.9) 710 124.1 (115.1–133.6) 355 139.1 (124.8–154.5) —†† —†† 175 118.2 (101.3–137.1) West Virginia 908 172.0 (160.9–183.5) 855 175.4 (163.8–187.5) 28 110.2 (73.1–159.3) —†† —†† —†† —†† —†† —†† West Alaska 424 169.4 (153.6–186.3) 232 158.0 (138.3–179.7) —†† —†† 25 138.7 (89.5–204.3) 115 217.2 (179.3–260.7) 40 232.0 (165.7–316.0) Arizona 3,590 168.8 (163.3–174.4) 1,683 176.1 (167.8–184.7) 130 122.4 (102.2–145.3) 1,454 164.4 (156.1–173.1) 199 164.2 (142.1–188.7) 79 132.7 (105.0–165.5) California 21,725 173.2 (170.9–175.6) 7,505 189.9 (185.6–194.2) 1,184 137.9 (130.1–146.0) 10,525 170.1 (166.9–173.4) 101 138.7 (112.8–168.8) 2,187 148.3 (142.1–154.6) Colorado 2,767 171.3 (165.0–177.8) 1,754 175.6 (167.4–184.0) 103 121.7 (99.3–147.6) 762 162.4 (151.1–174.5) 20 153.2 (93.2–237.6) 88 171.8 Hawaii 652 160.1 (148.0–172.9) 134 255.2 (213.7–302.4) —†† —†† 46 75.0 (54.3–101.0) —†† —†† 439 155.6 Idaho 941 170.0 (159.3–181.3) 789 178.3 (166.0–191.2) —†† —†† 121 136.5 (113.1–163.3) —†† —†† —†† —†† Montana 488 160.2 (146.2–175.0) 398 157.0 (141.9–173.2) —†† —†† 24 162.8 (104.0–242.7) 56 182.4 (137.7–237.0) —†† —†† New Mexico 1,077 157.0 (147.7–166.6) 393 198.7 (179.5–219.4) 20 126.9 (77.5–196.1) 539 139.7 (128.2–152.0) 101 131.0 (106.7–159.2) 16 186.7 (106.6–303.7) Oregon 2,114 182.6 (174.9–190.6) 1,591 192.1 (182.7–201.8) 40 111.6 (79.7–152.0) 343 155.1 (139.0–172.6) 27 134.5 (88.5–196.4) 81 146.1 (116.0–181.6) Utah 1,984 178.3 (170.5–186.4) 1,596 182.2 (173.3–191.3) 23 130.1 (82.1–195.9) 309 180.9 (161.1–202.5) —†† —†† 40 120.5 (86.0–164.0) Washington 3,797 180.7 (175.0–186.5) 2,656 189.8 (182.6–197.2) 163 135.8 (115.8–158.4) 542 146.9 (134.6–159.9) 83 200.1 (159.3–248.2) 276 158.1 (140.0–177.9) Wyoming 280 156.8 (139.0–176.3) 232 159.1 (139.3–181.0) —†† —†† 26 118.1 (76.8–173.4) —†† —†† —†† —†† Sources: CDC’s National Program of Cancer Registries; National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Abbreviations: AI/AN = American Indian/Alaska Native; API = Asian/Pacific Islander; CI = confidence interval. * Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population. † Cases included all malignant cancers (with behavior code = 3) as grouped by the International Classification of Childhood Cancer. § Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded. Registry-specific data quality information is available at https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2014-technical-notes.pdf. ¶ White, black, AI/AN, and API are non-Hispanic. Hispanic persons might be of any race. Counts exclude unspecified or unknown race/ethnicity; the counts in the total column may not equal the sum of the individual race/ethnicity columns. ** States are grouped by U.S. Census region. †† Case counts <16 are suppressed. §§ Race/ethnicity data was suppressed for states that elected to be excluded from race/ethnicity analysis. Pediatric cancer incidence rates varied by state within each cancer type (Figure). Incidence rates were highest in the West for leukemias, myeloproliferative diseases, and myelodysplastic diseases (ICCC group I) and in the Northeast for lymphomas and reticuloendothelial neoplasms (group II) and central nervous system cancers (group III). Rates were also highest in the Northeast for neuroblastoma, retinoblastoma, bone tumors, soft tissue sarcomas, and thyroid cancer (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/53586). Renal cancer rates were highest in the Northeast and South; hepatic tumor rates were highest in the Northeast and West. Germ cell tumor rates were highest in the West (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/53586). FIGURE Age-adjusted incidence* of cancer † among persons aged <20 years, by U.S. state and ICCC type — United States, § 2003–2014 ¶ Sources: CDC’s National Program of Cancer Registries; National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Abbreviation: ICCC = International Classification of Childhood Cancer. * Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population. † Cases included all malignant cancers (with behavior code = 3) as grouped by the ICCC. § Solid tumors (Groups IV–XI) include neuroblastoma and other peripheral nervous cell tumors, retinoblastoma, renal tumors, hepatic tumors, malignant bone tumors, soft tissue and other extraosseous sarcomas, germ cell and trophoblastic tumors and neoplasms of gonads, and other malignant epithelial neoplasms and melanomas. The ICCC group total map includes 258 cases not classified by ICCC. ¶ Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded. Registry-specific data quality information is available at https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2014-technical-notes.pdf. The figure above is a series of maps showing age-adjusted incidence rate of cancer among persons aged <20 years, by U.S. state and International Classification of Childhood Cancer type in the United States, during 2003–2014. Discussion This study used recent data with greater population coverage than past studies ( 4 , 5 ) to document geographic variation in pediatric cancer incidence rates by sex, age, type, and race/ethnicity. Consistent with past reports ( 1 , 4 , 5 ), pediatric cancer rates were highest in males, persons aged 0–4 years and 15–19 years, whites, and the Northeast U.S. Census region. Rates were highest in metropolitan areas with populations ≥1 million; state-based rates were highest in New Hampshire, DC, and New Jersey. A strength of this report is the use of extensive population-based surveillance data (>99% coverage §§ ), which permits a detailed description of state-based cancer incidence variation. Geographic variation in rates might account for differences in results from previous studies that were based on different populations such as state data ( 2 , 3 ), SEER registries (which cover 9%–28% of the U.S. population), ¶¶ or other large data sets ( 6 ). A 2016 study specific to Delaware assessed pediatric cancer incidence by demographic group and ZIP Code; the study commented on local environmental exposures and possible incidence disparities based upon sex, age, race/ethnicity, geographic location, and economic status ( 2 ). USCS data provide states with a standardized way to gauge whether local pediatric cancer incidence rates differ relative to other states and might prompt states to conduct investigations similar to the one performed in Delaware. Geographic variation in pediatric cancer incidence might be influenced by several factors.*** First, variation in childhood cancer incidence might be related to differences in exposures to carcinogenic chemicals (e.g., air pollution, secondhand smoke, food, or drinking water) or radiation ( 7 ). Second, genetic variation in certain populations (e.g., prevalence of cancer predisposition genes) ( 2 , 4 , 5 ) might contribute to geographic differences in cancer incidence. Third, the rates of certain cancer types might vary by race/ethnicity. For example, Hispanic children have the highest rate of the most common type of leukemia, pediatric acute lymphoblastic leukemia, and states with a higher proportion of Hispanics might have higher rates of acute lymphoblastic leukemia ( 8 ). Fourth, incidence of some types of cancer (e.g., thyroid carcinoma) might be related to enhanced detection and access to care, which can vary by geographic location ( 5 , 9 ). In addition, geographic variation might be affected by age, economic status, or rural/urban classification ( 4 , 8 , 10 ). Similar to the findings from this report, recent data detailing adult cancers also indicate that the highest cancer incidence rates are in the Northeast ( 10 ). Rates of cancer types mostly affecting adults also varied by rural/urban status; some of these differences in adults might be related to factors such as obesity or smoking ( 10 ), which might or might not also explain rural/urban variation in pediatric cancer. The findings in this report are subject to at least three limitations. First, Nevada was excluded because data for 2011 did not meet quality criteria, which limits the representativeness of the findings. Second, differences in diagnosis and cancer reporting among states might contribute to variation in cancer incidence rates ( 8 ). For example, states that were early adopters of electronic pathology reporting might report increased rates because of increased case ascertainment compared with other states. Finally, misrepresentation of race and ethnicity might exist; rate numerators might underestimate American Indians, Alaska Natives, and Hispanics, which could artificially lower rates among these groups; and U.S. Census populations used in rate denominators might undercount children and Hispanics, which could artificially increase rates in these populations ( 8 ). ††† Knowledge of pediatric cancer incidence variation by state and cancer type can prompt local and state cancer registries to evaluate reporting and diagnostic standards. Understanding geographic variation in incidence rates can help cancer control planners and clinicians address obstacles in access to care, which is especially relevant to states with large distances to pediatric oncology centers ( 3 ). Because 5-year pediatric cancer survival is >80%, and most cancer survivors require close monitoring by specialists throughout life ( 5 ), state-specific data by cancer type and patient age might help public health planners address ongoing chronic care needs. In addition, state-specific data by cancer type and patient age might help clinical trial organizers predict patient accrual. Finally, health care practitioners and researchers can use these data to guide investigations related to causes of pediatric cancer incidence variation ( 2 , 3 ). Continued surveillance will be needed to further validate findings and track geographic incidence patterns over time. Summary What is already known about this topic? Past research on nationwide pediatric cancer incidence described differences by U.S. Census region but did not provide state-level estimates. What is added by this report? During 2003–2014, the pediatric cancer rate was highest in the Northeast, lowest in the South, and highest in metropolitan areas with populations ≥1 million and counties in the top 25% economic status. Incidence rates by state ranged from 145 to 206 per million and were highest in New Hampshire, the District of Columbia, and New Jersey. The highest rate of leukemia was in the West; the highest rates of lymphoma and brain cancer were in the Northeast. What are the implications for public health practice? Knowledge of these geographic differences in childhood cancer incidence can be used to enhance provider awareness, treatment capacity, survivorship care, and cancer surveillance.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Rural-Urban Differences in Cancer Incidence and Trends in the United States

          Background: Cancer incidence and mortality rates in the United States are declining, but this decrease may not be observed in rural areas where residents are more likely to live in poverty, smoke, and forego cancer screening. However, there is limited research exploring national rural-urban differences in cancer incidence and trends.Methods: We analyzed data from the North American Association of Central Cancer Registries' public use dataset, which includes population-based cancer incidence data from 46 states. We calculated age-adjusted incidence rates, rate ratios, and annual percentage change (APC) for: all cancers combined, selected individual cancers, and cancers associated with tobacco use and human papillomavirus (HPV). Rural-urban comparisons were made by demographic, geographic, and socioeconomic characteristics for 2009 to 2013. Trends were analyzed for 1995 to 2013.Results: Combined cancers incidence rates were generally higher in urban populations, except for the South, although the urban decline in incidence rate was greater than in rural populations (10.2% vs. 4.8%, respectively). Rural cancer disparities included higher rates of tobacco-associated, HPV-associated, lung and bronchus, cervical, and colorectal cancers across most population groups. Furthermore, HPV-associated cancer incidence rates increased in rural areas (APC = 0.724, P < 0.05), while temporal trends remained stable in urban areas.Conclusions: Cancer rates associated with modifiable risks-tobacco, HPV, and some preventive screening modalities (e.g., colorectal and cervical cancers)-were higher in rural compared with urban populations.Impact: Population-based, clinical, and/or policy strategies and interventions that address these modifiable risk factors could help reduce cancer disparities experienced in rural populations. Cancer Epidemiol Biomarkers Prev; 27(11); 1265-74. ©2017 AACR.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008.

            In the past 3 decades, the incidence of thyroid cancer in the United States has been increasing. There has been debate on whether the increase is real or an artifact of improved diagnostic scrutiny. Our hypothesis is that both improved detection and a real increase have contributed to the increase. Because socioeconomic status (SES) may be a surrogate for access to diagnostic technology, we compared thyroid cancer incidence trends between high- and low-SES counties within the Surveillance, Epidemiology, and End Results 9 (SEER 9) registries. The incidence trends were assessed using joinpoint regression analysis. In high-SES counties, thyroid cancer incidence increased moderately (annual percentage change 1 [APC1]=2.5, p 4.0 cm, high- and low-SES counties had similar increasing incidence trends. Similarly, for tumors ≤2.0 cm, the incidence trends differed between counties that are in or adjacent to metropolitan areas and counties that are in rural areas, whereas for tumors >2.0 cm, all counties regardless of area of residence had similar increasing trends. Enhanced detection likely contributed to the increased thyroid cancer incidence in the past decades, but cannot fully explain the increase, suggesting that a true increase exists. Efforts should be made to identify the cause of this true increase.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014

              Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States, representing 20% of all cancers diagnosed in persons aged 3,000 new cases each year ( 1 ). Past studies reported increasing trends of ALL overall and among Hispanics, but these represented ≤28% of the U.S. population and did not provide state-based estimates ( 1 – 3 ). To describe U.S. ALL incidence rates and trends among persons aged <20 years during 2001–2014, CDC analyzed rigorous data (based on established publication criteria) from the United States Cancer Statistics data set, which includes incidence data on approximately 15,000 new cases per year of all types of invasive cancer among children and adolescents aged <20 years ( 4 ). The data set represented 98% of the U.S. population during the study period. Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million). Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014. ALL incidence was higher in the West than in any other U.S. Census region. State-specific data indicated that the highest rates of pediatric ALL incidence were in California, New Mexico, and Vermont. These demographic and geographic ALL incidence data might better inform public health interventions targeting the following areas: exposures to recognized risk factors for leukemia; ALL treatment, including clinical trial enrollment; survivorship care planning; and studies designed to understand the factors affecting changes in pediatric cancer incidence. The United States Cancer Statistics data set includes cancer incidence data from CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program ( 4 ). Data on new cases of cancer diagnosed during 2001–2014 were obtained from population-based cancer registries affiliated with the National Program of Cancer Registries or Surveillance, Epidemiology, and End Results programs. Incidence data for all registries except the District of Colombia, Mississippi, and Nevada met United States Cancer Statistics publication criteria during 2001–2014, and represented 98% of the U.S population.* This report includes cases diagnosed among children and adolescents aged <20 years and includes International Classification of Diseases for Oncology, Third Edition † codes 9728–9729, 9811–9818, and 9835–9837 as grouped by the International Classification of Childhood Cancer. § Cases were included if ALL was the first or only cancer diagnosed and was confirmed microscopically or by positive laboratory test or marker study. Recurrent cases of ALL were not included in this report. Age-adjusted rates were calculated using statistical software. All rates were expressed per 1 million persons and were age-adjusted to the 2000 U.S. standard population. ¶ Age-adjusted incidence trends were quantified using annual percent change (APC) calculated using joinpoint regression. Statistically significant APCs were different from zero (p<0.05). A maximum of two joinpoints were used to determine a change of direction in trends during the study period. Rates and trends were estimated by sex, age group, race/ethnicity, state, U.S. Census region,** county-level economic status, and rural/urban status. During 2001–2014, a total of 38,136 new pediatric ALL cases were diagnosed in the United States (Table). Overall incidence of ALL was 34.0 cases per 1 million. Rates were highest in children aged 1–4 years (75.2 per 1 million) and were higher in males (38.0) than in females (29.7). Among all racial/ethnic groups, the highest incidence rate (42.9 per 1 million) was among Hispanics, followed by non-Hispanic whites (34.2 per 1 million). The lowest incidence (18.7) occurred among non-Hispanic blacks. Pediatric ALL incidence rates in the 25% of U.S. counties with the highest economic status were higher than rates in the 25% of counties with the lowest economic status and were higher in metropolitan areas with ≥1 million persons than in nonmetropolitan areas. Rates were highest in the West (38.5) followed by the Northeast (34.8), Midwest (32.4), and South (31.6) Census regions, and, among states, were highest in Vermont (41.9), California (40.8), and New Mexico (39.1) (Figure 1) (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/47662). State-specific ALL incidence by race/ethnicity ranged from 10.1–27.9 per 1 million among non-Hispanic blacks to 25.1–45.0 among non-Hispanic whites and 27.3–48.5 among Hispanics (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/47663). TABLE Age-adjusted incidence* of acute lymphoblastic leukemia † in persons aged <20 years and annual percentage change (APC) in rates, by selected characteristics — United States, § 2001–2014 Characteristic No. Incidence (95% CI) APC¶ Years APC1 (95% CI) Years APC2 (95% CI) Years APC3 (95% CI) Overall 38,136 34.0 (33.6–34.3) 2001–2008 1.9 (0.5–3.3)** 2008–2014 -1.1 (-2.8–0.6) —†† — Sex Male 21,871 38.0 (37.5–38.5) 2001–2008 2.1 (0.5–3.7)** 2008–2014 -1.5 (-3.3–0.4) — — Female 16,265 29.7 (29.2–30.1) 2001–2003 -4.0 (-14.7–8.1) 2003–2008 3.2 (-0.5–7.0) 2008–2014 -1.0 (-2.9–0.9) Age group (yrs) <1 1,009 18.4 (17.3–19.6) 2001–2014 -1.5 (-3.3–0.3) —†† — — — 1–4 16,388 75.2 (74.0–76.4) 2001–2009 1.3 (-0.1–2.8) 2009–2014 -2.4 (-5.2–0.5) — — 5–9 9,535 34.8 (34.1–35.5) 2001–2010 2.2 (1.3–3.2)** 2010–2014 -1.7 (-4.6–1.3) — — 10–14 6,201 21.6 (21.1–22.1) 2001–2014 1.3 (0.5–2.1)** — — — — 15–19 5,003 17.0 (16.5–17.5) 2001–2014 0.4 (-0.5–1.3) — — — — Race/Ethnicity§§ White 21,843 34.2 (33.8–34.7) 2001–2014 0.3 (-0.3–0.9) — — — — Black 3,129 18.7 (18.0–19.3) 2001–2014 1.2 (-0.1–2.7) — — — — Hispanic 10,595 42.9 (42.1–43.7) 2001–2008 2.5 (0.3–4.7)** 2008–2014 -1.8 (-4.2–0.6) — — American Indian/Alaska Native 350 30.2 (27.1–33.6) 2001–2014 -1.9 (-4.2–0.5) — — — — Asian/Pacific Islander 1,765 31.6 (30.1–33.1) 2001–2014 0.3 (-0.9–1.6) — — — — U.S. Census region¶¶ Northeast —*** 34.8 (34.0–35.6) 2001–2007 3.0 (0.2–6.0)** 2007–2014 -1.6 (-3.7–0.7) — — Midwest — 32.4 (31.7–33.2) 2001–2011 1.6 (0.6–2.6)** 2011–2014 -5.4 (-11.4–1.0) — — South — 31.6 (31.0–32.1) 2001–2003 -4.6 (-15.3–7.6) 2003–2008 3.9 (0.2–7.7)** 2008–2014 -1.3 (-3.2–0.5) West — 38.5 (37.8–39.3) 2001–2014 0.4 (-0.3–1.1) — — — — County-level economic status by percentile (%) Bottom 25 4,182 32.2 (31.2–33.2) 2001–2014 1.4 (0.6–2.2)** — — — — 25–75 22,141 33.9 (33.4–34.3) 2001–2010 1.1 (0.2–2.1)** 2010–2014 -2.4 (-5.5–0.9) — — Top 25 10,646 34.9 (34.2–35.6) 2001–2008 2.9 (0.7–5.1)** 2008–2014 -1.5 (-4.0–1.1) — — Urban/Rural status Metropolitan area ≥1 million population 21,690 35.7 (35.3–36.2) 2001–2008 2.7 (1.2–4.2)** 2008–2014 -1.6 (-3.4–0.2) — — Metropolitan area 250,000 to <1 million population 8,134 34.4 (33.7–35.2) 2001–2011 0.8 (-0.4–2.1) 2011–2014 -4.4 (-11.8–3.7) — — Metropolitan area <250,000 population 3,302 33.8 (32.7–35.0) 2001–2014 0.6 (-0.3–1.5) — — — — Nonmetropolitan counties 4,962 32.9 (32.0–33.9) 2001–2014 0.9 (0.0–1.8) — — — — Source: CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Abbreviation: CI = confidence interval. * Per 1 million persons, age-adjusted to the 2000 U.S. standard population. † Cases included International Classification of Diseases for Oncology, Third Edition codes (9728–9729, 9811–9818, 9835–9837) as grouped by the International Classification of Childhood Cancer. § Incidence data are compiled from cancer registries that meet the data quality criteria for all years during 2001–2014 (covering approximately 98% of the U.S. population). Registry-specific data quality information is available at https://www.cdc.gov/cancer/npcr/uscs/data/00_data_quality.htm. Characteristic values with unknown, other, missing, or blank results are not included in this table. ¶ Trends were measured with APC in rates and were considered to increase or decrease if p<0.05; otherwise trends were considered stable. Trends were calculated using joinpoint regression, which allowed for different slopes in as many as three different periods, represented by APC1, APC2, and APC3, as applicable. The duration in years of APC1, APC2, and APC3 varied by study characteristic depending on joinpoint regression calculation. APC was not calculated if case count was <16 cases in any 1 year. ** p<0.05. †† Trend adequately described during 2001–2014 by previous APC columns. §§ White, black, American Indian/Alaska Native, and Asian/Pacific Islander persons are non-Hispanic. Hispanic persons might be of any race. ¶¶ Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. *** Number counts suppressed per United States Cancer Statistics complementary cell suppression rules: counts for national and regional data must be suppressed if a single state in a region or division is suppressed. FIGURE 1 Annual age-adjusted rates* of acute lymphoblastic leukemia among persons aged <20 years, by state — National Program of Cancer Registries, and Surveillance, Epidemiology, and End Results program, United States, 2001–2014 * Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population. The figure above is a map of the United States showing the annual age-adjusted rates of acute lymphoblastic leukemia among persons aged <20 years, by state, based on data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program, collected during 2001–2014. Overall pediatric ALL incidence increased 1.9% per year during 2001–2008, and then remained stable during 2008–2014 (Figure 2). Incidence increased among males during 2001–2008 and among children aged 5–9 years and 10–14 years during 2001–2010 and 2001–2014, respectively, as well as in metropolitan areas with populations ≥1 million during 2001–2008 (Table). Among Hispanics, rates increased during 2001–2008 (APC 2.5, 95% confidence interval = 0.3–4.7) and were stable (nonsignificant decrease) during 2008–2014; pediatric ALL incidence rates were stable in all other racial/ethnic groups. State-specific analysis indicated that pediatric ALL incidence increased during all or part of 2001–2014 in four states: Alabama, Maryland, Massachusetts, and New York (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/47662). FIGURE 2 Trends* in age-adjusted rates † of acute lymphoblastic leukemia in persons aged <20 years, by sex § and race/ethnicity ¶ — National Program of Cancer Registries, and Surveillance, Epidemiology, and End Results program, United States,** 2001–2014 * Trends were measured with annual percent change (APC) in rates, calculated using joinpoint regression, which allowed different slopes for as many as three different periods. † Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population. § APC for acute lymphoblastic leukemia for both sexes and for males was significantly different from zero during 2001–2008. ¶ APC for acute lymphoblastic leukemia for Hispanics was significantly different from zero during 2001–2008. ** Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2001–2014 (covering approximately 98% of the U.S. population). https://www.cdc.gov/cancer/npcr/uscs/data/00_data_quality.htm. The figure above consists of two line graphs showing the trends in age-adjusted rates of acute lymphoblastic leukemia in U.S. persons aged <20 years, by sex and race/ethnicity, based on data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program, collected during 2001–2014. Discussion Consistent with other published data, this analysis found that rates of ALL were highest in males, children aged 1–4 years, and Hispanics ( 1 ). Rates varied by state and region and were highest in the West U.S. Census Region. This report, using more recent data with broader population coverage than past studies ( 1 – 3 ), confirms an increase in pediatric ALL overall and among Hispanics (2001–2008) and also documents a subsequent period of stable trends overall and among Hispanics (2008–2014). High rates of pediatric ALL in the Hispanic population might explain high ALL rates in the West U.S. Census Region and in other specific states, given the high proportion of Hispanics in many of these areas. †† Past studies documenting increasing incidence of pediatric ALL in Hispanics focused on earlier periods using the Surveillance, Epidemiology, and End Results database or the California Cancer Registry ( 2 , 3 ). Recent stable trends in ALL rates in Hispanic populations (2008–2014) might indicate a change after 2 decades of documented increasing trends. The cause for the higher rates of ALL in Hispanic populations and the increase during 2001–2008 is unknown; however, past studies have evaluated such factors as genetic susceptibility, disproportionate environmental exposure to household chemicals, or racial and ethnic disparities in parents’ exposures to chemicals at work ( 2 , 3 ). Other studies have hypothesized that the increasing trends in obesity among Hispanics might explain the increasing trends of ALL incidence among this population ( 2 ). This report documents higher rates of ALL in persons aged <20 years living in counties in metropolitan areas with ≥1 million population and in counties in the top 25th income percentile. Past studies of pediatric leukemia have investigated possible associations with higher economic status or increased exposure to air pollution that is often found in large metropolitan areas ( 5 , 6 ). Etiologic studies examining potential causes of pediatric leukemia have documented associations between leukemia and exposures to solvents, traffic, pesticides, tobacco smoke, or radiation, or to specific nutritional exposures ( 7 ). The findings in this report are subject to at least five limitations. First, the District of Columbia, Mississippi, and Nevada were excluded because of incomplete trend data, which limits the representativeness of the results. Second, although the United States Cancer Statistics data publication standards yield high quality data, misclassifications of race and ethnicity exist and might underestimate rates in American Indians, Alaska Natives, and Hispanics ( 8 ); ongoing procedures are used to ensure that this information is as accurate as possible. Third, the U.S. Census population estimates used in rate denominators might undercount some groups, including children and Hispanics, which could artificially raise incidence rates ( 3 ). Fourth, improvement in case ascertainment through advancements in electronic pathology reporting might affect trends: rates might appear to increase because current cancer registration methods are more accurately recording cases that were previously under-recorded. Finally, the possibility of a statistical error exists when analyzing subgroups with small numbers. Although APCs that are close to the significance cutoff might be truly significant, future studies will be needed to validate and monitor trends. These recent state-based demographic cancer data can help local and national cancer control programs assess needs, allocate resources, and guide policy and public health strategies that can reduce cancer risk and improve the care of children and adolescents with ALL. Because cancer clinical trial participation has become an increasingly important part of quality clinical care ( 9 ), many state health departments have created cancer control plans that aim to address the economic and sociocultural barriers that limit certain groups enrolling in these trials. §§ Knowledge about rates and trends of pediatric ALL might help tailor the goals of these programs to address local and disease-specific needs. In addition, as incidence and survival of pediatric ALL increase ( 1 ), public health professionals can use recent ALL incidence data to improve local cancer survivorship programs that address chronic disease management, screen for late effects, and provide resources to help patients maintain a high quality of life ( 10 ). Public health planners can prioritize issues pertinent to pediatric cancer survivors such as transitioning to adult care and accessing the educational resources that might be available to these patients. Finally, health care professionals and researchers can use surveillance data to inform research questions. Continued surveillance data will be needed to further track incidence changes and public health needs relative to specific demographic groups and geographic areas. Summary What is already known about this topic? Acute lymphoblastic leukemia (ALL) is the most common cancer in children and adolescents in the United States. Past studies using ≤28% population coverage have described increasing incidence of pediatric ALL, especially in Hispanic populations. What is added by this report? Analysis of data covering 98% of the U.S. population indicated that the incidence of pediatric ALL increased during 2001–2008 overall and for Hispanics, but then was stable during 2008–2014. The cause for the higher rates of ALL in Hispanic populations and the increase during 2001–2008 is unknown. Incidence of pediatric leukemia during 2001–2014 was highest in the West U.S. Census Region, possibly reflecting the high proportion of Hispanics in many of the region’s constituent states. What are the implications for public health practice? Increasing incidence of pediatric ALL in certain demographic groups might necessitate changes to cancer control planning, affecting treatment and survivorship care. Continued cancer surveillance will be important in guiding future research, including etiologic studies.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb. Mortal. Wkly. Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                29 June 2018
                29 June 2018
                : 67
                : 25
                : 707-713
                Affiliations
                Epidemic Intelligence Service, CDC; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC.
                Author notes
                Corresponding author: David A. Siegel, dsiegel@ 123456cdc.gov , 770-488-4426.
                Article
                mm6725a2
                10.15585/mmwr.mm6725a2
                6023185
                29953430
                438148d0-6273-445e-911e-1bcd9f4bd901

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article